Long-term survival trends in solid cancers in the Nordic countries marking timing of improvements.
early diagnosis
periodic survival
prognosis
relative survival
treatment
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 05 2023
01 05 2023
Historique:
revised:
12
11
2022
received:
26
09
2022
accepted:
19
12
2022
pubmed:
27
12
2022
medline:
9
3
2023
entrez:
26
12
2022
Statut:
ppublish
Résumé
Survival studies are an important indicator of the success of cancer control. We analyzed the 5-year relative survival in 23 solid cancers in Denmark, Finland, Norway and Sweden over a 50-year period (1970-2019) at the NORDCAN database accessed from the International Agency for Research on Cancer website. We plotted survival curves in 5-year periods and showed 5-year periodic survival. The survival results were summarized in four groups: (1) cancers with historically good survival (>50% in 1970-1974) which include melanoma and breast, endometrial and thyroid cancers; (2) cancers which constantly improved survival at least 20% units over the 50 year period, including cancers of the stomach, colon, rectum, kidney, brain and ovary; (3) cancer with increase in survival >20% units with changes taking place in a narrow time window, including oral, oropharyngeal, testicular and prostate cancers; (4) the remaining cancers with <20% unit improvement in survival including lung, esophageal, liver, pancreatic, bladder, soft tissue, penile, cervical and vulvar cancers. For cancers in groups 1 and 2, the constant development implied multiple improvements in therapy, diagnosis and patient care. Cancers in group 3 included testicular cancers with known therapeutic improvements but for the others large incidence changes probably implied that cancer stage (prostate) or etiology (oropharynx) changed into a more tractable form. Group 4 cancers included those with dismal survival 50 years ago but a clear tendency upwards. In 17 cancers 5-year survival reached between 50% and 100% while in only six cancers it remained at below 50%.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1837-1846Informations de copyright
© 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68(21):8643-8653.
Allemani C, Weir HK, Carreira H, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977-1010.
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023-1075.
Hanna N, Einhorn LH. Testicular cancer: a reflection on 50 years of discovery. J Clin Oncol. 2014;32(28):3085-3092.
Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the “Immunoscore” in the classification of malignant tumours. J Pathol. 2014;232(2):199-209.
Pinsky PF. Principles of cancer screening. Surg Clin North Am. 2015;95(5):953-966.
Beyer T, Bidaut L, Dickson J, et al. What scans we will read: imaging instrumentation trends in clinical oncology. Cancer Imaging. 2020;20(1):38.
Hemminki K, Liu H, Hemminki A, Sundquist J. Power and limits of modern cancer diagnostics: cancer of unknown primary. Ann Oncol. 2012;23:760-764.
Ellis L, Woods LM, Estève J, Eloranta S, Coleman MP, Rachet B. Cancer incidence, survival and mortality: explaining the concepts. Int J Cancer. 2014;135(8):1774-1782.
Mariotto AB, Noone AM, Howlader N, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014;2014(49):145-186.
Baak JPA, Li H, Guo H. Clinical and biological interpretation of survival curves of cancer patients, exemplified with stage IV non-small cell lung cancers with long follow-up. Front Oncol. 2022;12:837419.
Henriksson M, Björnsson B, Sternby Eilard M, et al. Treatment patterns and survival in patients with hepatocellular carcinoma in the Swedish national registry SweLiv. BJS Open. 2020;4(1):109-117.
Tingstedt B, Andersson B, Jönsson C, et al. First results from the Swedish National pancreatic and periampullary cancer registry. HPB (Oxford). 2019;21(1):34-42.
Nymo LS, Myklebust T, Hamre H, Møller B, Lassen K. Treatment and survival of patients with pancreatic ductal adenocarcinoma: 15-year national cohort. BJS Open. 2022;6(2).
Dal Maso L, Panato C, Tavilla A, et al. Cancer cure for 32 cancer types: results from the EUROCARE-5 study. Int J Epidemiol. 2020;49(5):1517-1525.
Pukkala E, Engholm G, Hojsgaard Schmidt LK, et al. Nordic cancer registries: an overview of their procedures and data comparability. Acta Oncol. 2018;57:440-455.
Hemminki J, Försti A, Hemminki A, Hemminki K. Survival trends in solid cancers in the Nordic countries through 50 years. Eur J Cancer. 2022;175:77-85.
Engholm G, Ferlay J, Christensen N, et al. NORDCAN: a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49(5):725-736.
Storm HH, Engholm G, Hakulinen T, et al. Survival of patients diagnosed with cancer in the Nordic countries up to 1999-2003 followed to the end of 2006. A critical overview of the results. Acta Oncol. 2010;49(5):532-544.
Lundberg FE, Andersson TM, Lambe M, et al. Trends in cancer survival in the Nordic countries 1990-2016: the NORDCAN survival studies. Acta Oncol. 2020;59(11):1266-1274.
Engholm G, Gislum M, Bray F, Hakulinen T. Trends in the survival of patients diagnosed with cancer in the Nordic countries 1964-2003 followed up to the end of 2006. Material and Methods. Acta Oncol. 2010;49(5):545-560.
Krakowski I, Bottai M, Häbel H, et al. Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting. J Eur Acad Dermatol Venereol. 2021;35(1):105-115.
Henriksson R, Falkenius J, Norin S, et al. Register for new drugs in cancer care provides a picture of how the drugs are used in the daily clinical practice. Lakartidningen. 2017;114.
Koskinen AI, Hemminki O, Försti A, Hemminki K. Incidence and survival in oral and pharyngeal cancers in Finland and Sweden through half century. BMC Cancer. 2022;22(1):227.
Jakobsen KK, Grønhøj C, Jensen DH, et al. Increasing incidence and survival of head and neck cancers in Denmark: a nation-wide study from 1980 to 2014. Acta Oncol. 2018;57(9):1143-1151.
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92.
Grønhøj C, Jakobsen KK, Jensen DH, et al. Pattern of and survival following loco-regional and distant recurrence in patients with HPV+ and HPV− oropharyngeal squamous cell carcinoma: a population-based study. Oral Oncol. 2018;83:127-133.
Näsman A, Du J, Dalianis T. A global epidemic increase of an HPV-induced tonsil and tongue base cancer: potential benefit from a pan-gender use of HPV vaccine. J Intern Med. 2020;287(2):134-152.
You EL, Henry M, Zeitouni AG. Human papillomavirus-associated oropharyngeal cancer: review of current evidence and management. Curr Oncol. 2019;26(2):119-123.
Maconachie R, Mercer T, Navani N, McVeigh G. Lung cancer: diagnosis and management: summary of updated NICE guidance. BMJ. 2019;364:l1049.
Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335-49.e15.
Jeremiasen M, Linder G, Hedberg J, et al. Improvements in esophageal and gastric cancer care in Sweden-population-based results 2007-2016 from a national quality register. Dis Esophagus. 2020;33(3).
Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008-2020.
Villanueva A, Longo DL. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450-1462.
Allum W, Lordick F, Alsina M, et al. ECCO essential requirements for quality cancer care: oesophageal and gastric cancer. Crit Rev Oncol Hematol. 2018;122:179-193.
Kalff MC, Gottlieb-Vedi E, Verhoeven RHA, et al. Presentation, treatment, and prognosis of esophageal carcinoma in a nationwide comparison of Sweden and The Netherlands. Ann Surg. 2021;274(5):743-750.
Hemminki K, Försti A, Hemminki A. Survival in colon and rectal cancers in Finland and Sweden through 50 years. BMJ Open Gastroenterol. 2021;8(1):e000644.
Cardoso R, Guo F, Heisser T, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. Lancet Oncol. 2021;22(7):1002-1013.
Babaei M, Jansen L, Balavarca Y, et al. Neoadjuvant therapy in rectal cancer patients with clinical stage II to III across European countries: variations and outcomes. Clin Colorectal Cancer. 2018;17(1):e129-e142.
Glimelius B, Holm T, Blomqvist L. Chemotherapy in addition to preoperative radiotherapy in locally advanced rectal cancer: a systematic overview. Rev Recent Clin Trials. 2008;3(3):204-211.
Birgisson H, Talbäck M, Gunnarsson U, Påhlman L, Glimelius B. Improved survival in cancer of the colon and rectum in Sweden. Eur J Surg Oncol. 2005;31(8):845-853.
Dahlberg M, Påhlman L, Bergström R, Glimelius B. Improved survival in patients with rectal cancer: a population-based register study. Br J Surg. 1998;85(4):515-520.
DeStefanis RA, Kratz JD, Emmerich PB, Deming DA. Targeted therapy in metastatic colorectal cancer: current standards and novel agents in review. Curr Colorectal Cancer Rep. 2019;15(2):61-69.
Hemminki K, Försti A, Hemminki A, Ljungberg B, Hemminki O. Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden. PLoS One. 2021;16(6):e0253236.
Thorstenson A, Harmenberg U, Lindblad P, Holmstrom B, Lundstam S, Ljungberg B. Cancer characteristics and current treatments of patients with renal cell carcinoma in Sweden. Biomed Res Int. 2015;2015:456040.
Hemminki O, Perlis N, Bjorklund J, Finelli A, Zlotta AR, Hemminki A. Treatment of advanced renal cell carcinoma: immunotherapies have demonstrated overall survival benefits while targeted therapies have not. Eur Urol Open Sci. 2020;22:61-72.
Malmstrom PU, Gardmark T, Sherif A, et al. Incidence, survival and mortality trends of bladder cancer in Sweden 1997-2016. Scand J Urol. 2019;53(4):193-199.
Malmström PU, Rintala E, Wahlqvist R, Hellström P, Hellsten S, Hannisdal E. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic cystectomy trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol. 1996;155(6):1903-1906.
Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(12):1856-1883.
Low JT, Ostrom QT, Cioffi G, et al. Primary brain and other central nervous system tumors in the United States (2014-2018): a summary of the CBTRUS statistical report for clinicians. Neurooncol Pract. 2022;9(3):165-182.
IARC. Breast Cancer Screening. Lyon: IARC Press; 2016:469.
Nordenskjöld AE, Fohlin H, Arnesson LG, et al. Breast cancer survival trends in different stages and age groups - a population-based study 1989-2013. Acta Oncol. 2019;58(1):45-51.
Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Breast. 2017;31:244-259.
Dursun P, Ayhan A. Gynecologic oncologist perspective about ESMO-ESGO-ESTRO consensus conference on endometrial cancer. Int J Gynecol Cancer. 2017;27(4):826-831.
Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi24-vi32.
Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169-182.
Hemminki K, Kanerva A, Försti A, Hemminki A. Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment. BMC Cancer. 2022;22(1):456.
Tandstad T, Kollmannsberger CK, Roth BJ, et al. Practice makes perfect: the rest of the story in testicular cancer as a model curable neoplasm. J Clin Oncol. 2017;35(31):3525-3528.
Parker C, Castro E, Fizazi K, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119-1134.
van Poppel H, Watkin NA, Osanto S, Moonen L, Horwich A, Kataja V. Penile cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi115-vi124.
de Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15(1):23-34.